Clinical Trials
The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.
Clinical Trials for Kidney Recipients
- Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Sponsor: Allovir
Organ Type: All organs
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: Saturday, March 30, 2024
Other Requirements
- Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Other Requirements
COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
- Interleukin 6 blockade Modifying Antibody mediated Graft INjury and eGFR decline (IMAGINE)
Sponsor: CSL Behring
Organ Type: Kidney
Ages Accepted: 18 years old to 70 years old
Genders Accepted: Both male and female
Expected Study Completion Date: April 2028
- A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
Sponsor: Medeor Therapeutics, Inc.
Organ Type: Kidney
Ages Accepted: Age ≥18 and ≤70 years
Genders Accepted: Both male and female
Expected Study Completion Date: January 2022
- A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)
Sponsor: Novartis
Organ Type: Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: July 28, 2026 - A Randomized, Controlled, Multi-center, Safety and Efficacy Study of FCR001 Cell-based Therapy Relative to a Tacrolimus and Mycophenolate-based Regimen in de Novo Living Donor Renal Transplant Recipients, and Safety in FCR001 Donors (FREEDOM-1)
Sponsor: Talaris Therapeutics
Organ Type: Living Donor Kidney
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: April 30, 2025
Clinical Trials for Other Organ Types
- Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Dosing Interval, 3-period Study of the Safety, Tolerability and Effectiveness of Adoptively Transferred ALVR105 (Viralym-M) Multivirus-specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia
Sponsor: Allovir
Organ Type: All organs
Ages Accepted: 18+
Genders Accepted: Both male and female
Expected Study Completion Date: Saturday, March 30, 2024
Other Requirements
- Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
Sponsor: Atara Biotherapeutics
Organ Type: All organs
Ages Accepted: All ages
Genders Accepted: Both male and female
Expected Study Completion Date: Wednesday, June 30, 2027
Other Requirements
COVID-19 Update: The ALLELE trial remains open and is currently enrolling patients. Please visit clinicaltrials.gov for information regarding sites and investigators.
- A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
Sponsor: Takeda Pharmaceutical Company Limited
Organ Type: Hematopoietic Stem Cell Transplant
Ages Accepted: ≥16 years of age
Genders Accepted: Both male and female
Expected Study Completion Date: Tuesday, August 13, 2021
Other Requirements
- A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of an Anti-CD40 Monoclonal Antibody, CFZ533 vs. Standard of Care Control, in Adult de Novo Liver Transplant Recipients With a 12-month Additional Follow-up (CONTRAIL I)
Sponsor: Novartis
Organ Type: Liver
Ages Accepted: 18 years to 70 years
Genders Accepted: Both male and female
Expected Study Completion Date: April 26, 2023
- A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101 Administered Intravenously or Subcutaneously in Healthy Subjects
Sponsor: Veloxis Pharmaceuticals
Organ Type: Other - Healthy Participants
Ages Accepted: 18 years to 65 years
Genders Accepted: Both male and female
Expected Study Completion Date: Monday, October 31, 2022